Literature DB >> 2260096

Toxicological studies on a benzofurane derivative. II. Demonstration of peroxisome proliferation in rat liver.

E G Butler1, T Ichida, H Maruyama, R Schulte-Hermann, G M Williams.   

Abstract

The uricosuric drug benzbromarone (3,5-dibromo-4-hydroxyphenyl)-1-(2-ethyl-3-benzofuranyl)methanone, a benzofurane derivative, was studied for its effects on parameters related to hepatic peroxisome proliferation. Groups of male F-344 rats were fed either basal diet, the peroxisome proliferator clofibrate at 5000 ppm as a comparison compound, or benzbromarone at two doses, 1000 and 2000 ppm. Benzbromarone and clofibrate produced hepatomegaly and increases in the activities of catalase, acyl CoA oxidase, malate dehydrogenase, and glycerol-3-phosphate dehydrogenase. Benzbromarone and clofibrate also both induced similar histologic and ultrastructural changes in hepatocytes, including induction of peroxisomes. Therefore, benzbromarone acted as a peroxisome-proliferating agent in rats under these conditions. Benzbromarone differs from other peroxisome proliferators in its chemical structure, uricosuric action, and the morphology of liver peroxisomes that were induced by exposure.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2260096     DOI: 10.1016/0041-008x(90)90344-t

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  3 in total

1.  Benzbromarone, an old uricosuric drug, inhibits human fatty acid binding protein 4 in vitro and lowers the blood glucose level in db/db mice.

Authors:  Hai-yan Cai; Ting Wang; Jian-chun Zhao; Peng Sun; Gui-rui Yan; Hai-peng Ding; Ying-xia Li; He-yao Wang; Wei-liang Zhu; Kai-xian Chen
Journal:  Acta Pharmacol Sin       Date:  2013-09-30       Impact factor: 6.150

Review 2.  A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?

Authors:  Ming-Han H Lee; Garry G Graham; Kenneth M Williams; Richard O Day
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

3.  Activating effect of benzbromarone, a uricosuric drug, on peroxisome proliferator-activated receptors.

Authors:  Chiyoko Kunishima; Ikuo Inoue; Toshihiro Oikawa; Hiromu Nakajima; Tsugikazu Komoda; Shigehiro Katayama
Journal:  PPAR Res       Date:  2007       Impact factor: 4.964

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.